We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Chromosome Interaction Profiling Reveals Cancer Risk Genes

By LabMedica International staff writers
Posted on 29 Mar 2018
Breast cancer is a heterogeneous disease with two main subtypes defined by the presence (ER+) or absence (ER−) of the estrogen receptor. More...
Approximately 80% of newly diagnosed breast cancers are ER+ although this proportion varies with age at diagnosis and ethnicity.

Genome-wide association studies (GWAS) coupled with large-scale replication and fine-mapping studies have led to the identification of approximately 100 breast cancer risk loci. Potential target and survival-related genes in breast cancer have been identified using chromatin interaction profiles to map parts of the genome previously implicated in risk of the disease.

A team of scientists led by those at the Institute of Cancer Research (London, UK) used a long-range interaction profiling technique called Capture Hi-C (CHi-C) to investigate dozens of regions previously implicated in breast cancer risk. Based on CHi-C data for four breast cancer cell lines with or without enhanced estrogen receptor (ER) activity, a cancer-free breast epithelial cell line, and a cell line from another tissue type, they focused in on 110 potential target genes at 33 of the risk loci.

By adding in related risk single nucleotide polymorphism (SNP) data, RNA sequence profiles, and somatic mutation data reported previously, the team looked at overlap between these proposed targets, expression quantitative trait loci (eQTL), and genes prone to mutation in breast cancer tumors. With the help of gene expression and outcome data from the Metabric breast cancer cohort, meanwhile, the authors highlighted 32 genes with ties to breast cancer survival time. After using HiSeq2000 instruments to sequence target-enriched Hi-C libraries, the team tallied the CHi-C interaction peaks at each risk locus. A dozen risk loci lacked discernable interaction peaks, leaving interaction peaks at 51 loci for further consideration within and across the six cell lines.

The team uncovered potential gene targets at 33 of the breast cancer-associated sites, spanning 94 protein-coding and 16 non-coding RNA gene targets neighboring the risk loci or falling more far afield. They subsequently considered the target genes alongside eQTLs (informed by RNA sequence data from the Cancer Genome Atlas) and somatic mutation profiles identified in hundreds of breast cancer genome sequences, which supported the notion that CHi-C can help unearth authentic target genes.

The authors concluded that a high-throughput CHi-C analysis can contribute to on-going efforts to functionally annotate GWAS risk loci and that CHi-C target genes that are supported by additional data sources are strong candidates for in-depth functional follow-up studies. The study was published on March 12, 2018, in the journal Nature Communications.

Related Links:
Institute of Cancer Research


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.